Core Viewpoint - The company, Chaoyue Eye Care (02219), has announced a share buyback program, indicating confidence in its business outlook and potential to create value for shareholders [1] Summary by Sections Share Buyback Authorization - The board of directors has resolved to repurchase up to HKD 50 million worth of company shares starting from November 17, 2025, based on the authorization approved at the annual general meeting on June 6, 2025 [1] - The board may increase the maximum purchase amount under the buyback authorization depending on market conditions, with timely announcements to be made as necessary [1] Financial Position - The board believes that the company's existing financial resources are sufficient to implement the share buyback while maintaining a robust financial position [1]

Core Viewpoint - The company has updated its share buyback plan, indicating confidence in its long-term growth and market performance, as the current stock price is perceived to be below its true value [1] Group 1: Share Buyback Plan - The updated share buyback plan allows the company to repurchase up to 25,461,295 shares over a period of 50 trading days starting from November 13, 2025 [1] - The total shares to be repurchased, including those already bought back in 2025, will represent 5% of the total issued shares as of the authorization date [1] Group 2: Management Confidence - The board believes that the share buyback plan reflects the confidence of the directors and senior management in the company's long-term growth and market performance [1] - The board asserts that the buyback plan is in the best interest of the company and its shareholders [1] Group 3: Shareholder Activity - The company has been informed that Yijie Biotechnology Holdings Limited and its concert parties have cumulatively purchased 100,000 shares between November 6 and November 10, 2025 [1] - Following this purchase, the concert group holds a total of 218,048,730 shares, representing approximately 37.92% of the total issued shares (excluding treasury shares) [1] - The board views this increase in shareholding as a sign of confidence from major shareholders regarding the company's prospects and growth potential [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本 公 司 董 事 會（「董事會」）認 為 本 公 司 目 前 股 價 嚴重低估 本 公 司 的 價 值。憑 藉 對 本 公 司 未 來 發 展 前 景 的 充 分 信 心 及 對 本 公 司 內 在 價 值 的 高 度 認 同，為 持 續 增 強 市 場 對本公司的信心並提升本公司的投資價值，根據本公司股東於2025年6月20日舉行 的股東週年大會上 批 准 授 予 本 公 司 董 事（「董 事」）的股份購回授權，本公司已於2025 年11月6日至本公告日期在香港聯合交易所有限公司購回合共549,800股普通股作 為庫存股。所購回的股份佔本公司於本公告日期的現有已發行股份總數約0.24%。 於本公告日期，購回涉及的 總 金額為 約11.07百萬港元（不包括佣金及其他開支）。 股 東 及 潛 在 投 資 者 應 注 意，本 公 司 進 行 場 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 本公司董事（「董事」）會（「董事會」）有意宣佈，根據董事獲授出的一般授權（「股 份購回授權」，由股東於2025年6月12日舉行的股東週年大會上批准），董事會於 2025年11月7日決議不時自公開市場購回本公司普通股（「股份」），購回股份的金 額最高為30百萬港元。股份購回授權將持續有效，直至以下最早發生者為止：(i) 本公司下屆股東週年大會結束時；(ii)根據適用法律或本公司組織章程細則規定本 公司須舉行下屆股東週年大會期限屆滿時；或(iii)股東於本公司股東大會上以普 通決議案變更或撤銷該項授權時。股份購回授權的詳情載於本公司日期為2025年 5月21日的通函。 截至本公告日期，本公司根據股份購回授權購回1,681,000股股份並持作庫存股 份。股東及潛在投資者應注意，本公司之場內股份購回將視乎市況進行，並將由 董事會及╱或其授權人士全權酌情決定。概無法保證任何購回 ...

Core Viewpoint - The company plans to repurchase shares worth up to HKD 200 million in the open market, reflecting confidence in its business outlook and aiming to enhance shareholder returns [1] Group 1: Share Repurchase Details - The share repurchase will occur over a six-month period starting from the date of the announcement [1] - The total number of shares to be repurchased will not exceed 223 million shares, which is approximately 10% of the total shares issued as of the shareholders' annual meeting date [1] Group 2: Financial Health and Market Conditions - The company currently has a stable cash flow and overall financial condition, which supports its ongoing business development needs [1] - The board believes that the shares are undervalued in the market, justifying the repurchase decision [1]

公司现时资金流量稳健，整体财务状况稳定，可满足公司业务持续发展的需求。董事会认为，于市场上 买卖的股份价值被低估。董事会亦认为，股份购回可展示公司对其业务展望及前景充满信心及提高对股 东的回报，从而将使公司受益，并为股东创造价值，符合公司及股东的整体利益。 格隆汇11月3日丨粉笔(02469.HK)发布公告，根据股东于股东周年大会上所授出的一般授权，董事会有 意自本公告日期起的六个月期间于公开市场以不多于2亿港元购回股份，惟须视乎市场状况及公司的资 金安排。股份购回总数将不超过约2.23亿股股份(相当于公司于股东周年大会日期已发行股份(不包括库 存股份(如有))总数10%)。 ...

Core Viewpoint - The company, 美丽田园医疗健康 (02373.HK), has repurchased shares, indicating management's confidence in the long-term value of the business and aiming to enhance shareholder returns [1] Summary by Relevant Sections Share Buyback Details - On October 27, 2025, the company repurchased 40,000 shares at a total transaction amount of approximately HKD 1,244,090, with an average price of about HKD 31.10 per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 415,000 shares for approximately HKD 13,224,850 [1] Management's Perspective - The board believes that the current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The share buyback is seen as beneficial for the overall interests of the company and its shareholders, reinforcing management's commitment to the company's long-term value [1]

Core Viewpoint - The company believes that the recent share buyback reflects management's confidence in the long-term value of the business and aims to enhance market value and shareholder returns [1] Summary by Sections Share Buyback Details - On October 21, 2025, the company repurchased 50,000 shares at a total transaction amount of approximately HKD 1,565,530, with an average price of about HKD 31.31 per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 260,000 shares for a total consideration of approximately HKD 8,423,710 [1] Management's Perspective - The board believes that the current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The share buyback is seen as beneficial for the overall interests of the company and its shareholders [1]

Core Viewpoint - Coolpad Group (02369) announced a share buyback plan to promote sustainable operations and maximize shareholder value, reflecting the board's confidence in the company's long-term business prospects [1] Summary by Relevant Sections - **Share Buyback Plan** - The board has decided to repurchase shares in the open market, with the actual buyback price not exceeding 5% above the average closing price of the shares over the preceding five trading days [1] - The buyback plan is seen as aligning with the overall best interests of the company and its shareholders [1] - **Management Confidence** - The management team expresses strong confidence in the group's future prospects and growth [1] - **Authorization Update** - The board intends to update the existing buyback authorization to allow for the repurchase of more shares as needed [1] - A special general meeting will be convened to seek shareholder approval for the update and revision of the existing buyback authorization [1]

Core Viewpoint - Coolpad Group (02369) announced a share buyback plan to promote sustainable operations and maximize shareholder value, reflecting the board's confidence in the company's long-term business prospects [1] Group 1: Share Buyback Plan - The board has decided to repurchase shares in the open market, with the actual buyback price not exceeding 5% of the average closing price of the shares over the five trading days preceding each buyback [1] - The share buyback plan is seen as aligning with the overall best interests of the company and its shareholders [1] Group 2: Management Confidence - The management team expresses strong confidence in the group's future prospects and growth [1] - The board believes that the share buyback plan reflects this confidence and is a strategic move for the company's development [1] Group 3: Authorization Update - The board plans to update the existing buyback authorization to allow for the repurchase of more shares as needed [1] - A special shareholders' meeting will be convened to seek approval for the update and revision of the existing buyback authorization [1]